Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries

Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2363-70. doi: 10.1152/ajpheart.01042.2007. Epub 2008 Mar 28.

Abstract

The perivascular sensory nerve (PvN) Ca(2+)-sensing receptor (CaR) is implicated in Ca(2+)-induced relaxation of isolated, phenylephrine (PE)-contracted mesenteric arteries, which involves the vascular endogenous cannabinoid system. We determined the effect of inhibition of diacylglycerol (DAG) lipase (DAGL), phospholipase A(2) (PLA(2)), and cytochrome P-450 (CYP) on Ca(2+)-induced relaxation of PE-contracted rat mesenteric arteries. Our findings indicate that Ca(2+)-induced vasorelaxation is not dependent on the endothelium. The DAGL inhibitor RHC 802675 (1 microM) and the CYP and PLA(2) inhibitors quinacrine (5 microM) (EC(50): RHC 802675 2.8 +/- 0.4 mM vs. control 1.4 +/- 0.3 mM; quinacrine 4.8 +/- 0.4 mM vs. control 2.0 +/- 0.3 mM; n = 5) and arachidonyltrifluoromethyl ketone (AACOCF(3), 1 microM) reduced Ca(2+)-induced relaxation of mesenteric arteries. Synthetic 2-arachidonoylglycerol (2-AG) and glycerated epoxyeicosatrienoic acids (GEETs) induced concentration-dependent relaxation of isolated arteries. 2-AG relaxations were blocked by iberiotoxin (IBTX) (EC(50): control 0.96 +/- 0.14 nM, IBTX 1.3 +/- 0.5 microM) and miconazole (48 +/- 3%), and 11,12-GEET responses were blocked by IBTX (EC(50): control 55 +/- 9 nM, IBTX 690 +/- 96 nM) and SR-141716A. The data suggest that activation of the CaR in the PvN network by Ca(2+) leads to synthesis and/or release of metabolites of the CYP epoxygenase pathway and metabolism of DAG to 2-AG and subsequently to GEETs. The findings indicate a role for 2-AG and its metabolites in Ca(2+)-induced relaxation of resistance arteries; therefore this receptor may be a potential target for the development of new vasodilator compounds for antihypertensive therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Acetylcholine / pharmacology
  • Animals
  • Arachidonic Acids / metabolism*
  • Arachidonic Acids / pharmacology
  • Calcium / metabolism*
  • Cytochrome P-450 Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System / metabolism*
  • Dose-Response Relationship, Drug
  • Endocannabinoids
  • Enzyme Inhibitors / pharmacology
  • Glycerides / metabolism*
  • Lipoprotein Lipase / antagonists & inhibitors
  • Lipoprotein Lipase / metabolism
  • Male
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / enzymology
  • Mesenteric Arteries / metabolism*
  • Miconazole / pharmacology
  • Peptides / pharmacology
  • Phenylephrine / pharmacology
  • Phospholipase A2 Inhibitors
  • Phospholipases A2 / metabolism
  • Piperidines / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels, Calcium-Activated / antagonists & inhibitors
  • Potassium Channels, Calcium-Activated / metabolism
  • Pyrazoles / pharmacology
  • Quinacrine / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptors, Calcium-Sensing / metabolism*
  • Rimonabant
  • Signal Transduction* / drug effects
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation*
  • Vasodilator Agents / pharmacology

Substances

  • Arachidonic Acids
  • Cytochrome P-450 Enzyme Inhibitors
  • Endocannabinoids
  • Enzyme Inhibitors
  • Glycerides
  • Peptides
  • Phospholipase A2 Inhibitors
  • Piperidines
  • Potassium Channel Blockers
  • Potassium Channels, Calcium-Activated
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptors, Calcium-Sensing
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • arachidonyltrifluoromethane
  • Phenylephrine
  • iberiotoxin
  • Miconazole
  • glyceryl 2-arachidonate
  • Cytochrome P-450 Enzyme System
  • Lipoprotein Lipase
  • Phospholipases A2
  • 8,11,14-Eicosatrienoic Acid
  • Quinacrine
  • Acetylcholine
  • Rimonabant
  • Calcium